EISAI R& D MANAGEMENT CO. LTD.;NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
发明人:
申请号:
IL26008318
公开号:
IL260083D0
申请日:
2018.06.17
申请国别(地区):
IL
年份:
2018
代理人:
摘要:
The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.